Pioneering Medicines president Paul Biondi (Flagship via YouTube)

Flag­ship and the Cys­tic Fi­bro­sis Foun­da­tion team up on a nov­el re­search pact to chase down po­ten­tial cures

Amid Mod­er­na’s quick rise to the top, the in­vestor be­hind the firm, Flag­ship Pi­o­neer­ing, has nev­er been more promi­nent or un­shake­ably con­fi­dent. Now, look­ing to crack the code on a cure for cys­tic fi­bro­sis, the uber-in­cu­ba­tor is part­ner­ing up with a lead­ing non­prof­it to chase the im­pos­si­ble.

Flag­ship’s Pi­o­neer­ing Med­i­cines unit and the Cys­tic Fi­bro­sis Foun­da­tion will team up on a nov­el in­dus­try-non­prof­it col­lab­o­ra­tion to pur­sue ther­a­peu­tic break­throughs in the crip­pling lung dis­ease, with the non­prof­it pony­ing up $110 mil­lion in R&D fund­ing for a planned new­co, the part­ners said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA